Dyax's HAE drug succeeds in second Phase III trial
This article was originally published in Scrip
Executive Summary
Dyax's lead investigational hereditary angioedema (HAE) drug DX-88 (ecallantide) has met the primary endpoint of its second Phase III trial, and the company intends to submit a BLA to the FDA early in the fourth quarter of 2008. Shares in the US-based biotech company rose 15% on the news of the trial results, closing at $5.00 on Nasdaq on August 18th.
You may also be interested in...
Amgen reveals more details of denosumab's fracture benefit
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Gilead must conduct another study of cystic fibrosis drug, FDA says
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.